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Introduction
Paclitaxel (Taxol) and derivatives are active against various
tumors (1–6) and have also been used to treat malignant
glioma and brain metastases (7–9). However, brain tumors
constitute a difficult problem and the therapeutic benefit
of paclitaxel has been variable and low. This could be attrib-
uted to its limited entry into the CNS. Although paclitax-
el is very lipophilic, concentrations in the CNS are very low
after intravenous administration (10, 11).
Paclitaxel appears to be a substrate of the mul-
tidrug resistance protein p-gp (12–14), and it is like-
ly that this transporter contributes to its limited
access to the brain. P-gp is expressed in high levels in
cultured brain capillary endothelial cells and in
intact brain capillaries (15, 16). It is localized at the
luminal surface of the endothelium (17, 18), and
therefore is in the correct location to restrict perme-
ation of a variety of drugs into the CNS (19–21). Ani-
mals with reduced p-gp function show an accumula-
tion of p-gp substrates in the brain as well as a
markedly increased sensitivity to neurotoxic p-gp
substrates, e.g., ivermectin (18, 22, 23).
The present study identifies in vitro a mechanism that
limits paclitaxel access to the CNS and outlines a strat-
egy to circumvent it by blocking p-gp. We demonstrat-
ed that the p-gp blocker valspodar enhances paclitaxel
entry into the brains of mice after intravenous dosing
and that valspodar dramatically increases paclitaxel
effectiveness against a human glioblastoma implanted
into the CNS of nude mice. These are the first data
directly demonstrating the role of p-gp in limiting the
therapeutic availability of paclitaxel to the CNS.
Methods
Chemicals. Valspodar (SDZ PSC 833) and the fluores-
cent cyclosporin derivative NBDL-CS were from
Novartis Pharma GmbH (Nürnberg, Germany and
Basel, Switzerland). Paclitaxel, BODIPY Fl-paclitaxel,
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Paclitaxel concentrations in the brain are very low after intravenous injection. Since paclitaxel is exclud-
ed from some tumors by p-glycoprotein (p-gp), the same mechanism may prevent entry into the brain.
In vitro, paclitaxel transport was examined in capillaries from rat brains by confocal microscopy using
BODIPY Fl-paclitaxel. Western blots and immunostaining demonstrated apical expression of p-gp in
isolated endothelial cells, vessels, and tissue. Secretion of BODIPY Fl-paclitaxel into capillary lumens
was specific and energy-dependent. Steady state luminal fluorescence significantly exceeded cellular
fluorescence and was reduced by NaCN, paclitaxel, and SDZ PSC-833 (valspodar), a p-gp blocker.
Leukotriene C4 (LTC4), an Mrp2-substrate, had no effect. Luminal accumulation of NBDL-cyclosporin,
a p-gp substrate, was inhibited by paclitaxel. In vivo, paclitaxel levels in the brain, liver, kidney, and plas-
ma of nude mice were determined after intravenous injection. Co-administration of valspodar led to
increased paclitaxel levels in brains compared to monotherapy. Therapeutic relevance was proven for
nude mice with implanted intracerebral human U-118 MG glioblastoma. Whereas paclitaxel did not
affect tumor volume, co-administration of paclitaxel (intravenous) and PSC833 (peroral) reduced tumor
volume by 90%. Thus, p-gp is an important obstacle preventing paclitaxel entry into the brain, and inhi-
bition of this transporter allows the drug to reach sensitive tumors within the CNS.
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and calcein-AM were from Molecular Probes Europe
BV (Leiden, The Netherlands).
Capillary isolation. Capillaries from male Wistar rat
brains were isolated at 4°C in pregassed (95% O2/5%
CO2) solutions as described (18). Briefly, pieces of cor-
tical gray matter were homogenized in three volumes
(vol/wt) of buffer A (103 mM NaCl, 4.7 mM KCl, 2.5
mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 15 mM
HEPES), and, after addition of dextran (final concen-
tration 30%), the homogenate was centrifuged at low
speed. The pellet was resuspended in buffer A supple-
mented with 25 mM NaHCO3, 10 mM glucose, 1 mM
Na-pyruvate, 0.5% (wt/vol) BSA, and filtered through a
200-µm nylon mesh. The filtrate was passed over a
glass bead column, and after washing, capillaries adher-
ing to the beads were collected by gentle agitation. Cap-
illaries were centrifuged, the pellet was resuspended in
ice-cold, BSA-free Krebs-Henseleit buffer (KHB) and
immediately used for transport experiments.
Fluorescence microscopy. Capillaries were transferred to
a Teflon incubation chamber, containing 0.5–1.0 ml of
Krebs-Ringer medium with fluorescent compounds
and transport effectors. Fluorescent compounds and
inhibitors were added to the incubation medium in
DMSO stock solutions. Earlier experiments showed
that DMSO concentrations less than or equal to 0.5%
had no significant effect on transport. The chamber
floor was a 2 × 2–cm glass coverslip through which the
tissue could be observed by a confocal laser scanning
microscope (LSM 5 Pascal, 488-nm laser line, 515-nm
long-pass emission filter; Carl Zeiss Jena GmbH, Jena,
Germany). A low laser intensity (<3% of maximum)
was used to avoid photobleaching. Tissue autofluo-
rescence was not detectable. The images were analyzed
with the Scion Image software (Beta 3; Scion Corp.,
Frederick, Maryland, USA). Epifluorescent images of
capillaries were acquired by averaging four to eight
frames. Earlier, using fluorescein as reference com-
pound, it was shown that fluorescence intensity and
fluorescein concentration had an approximately linear
relationship (24). Here, the data are given as average of
measured pixel intensity rather than estimated con-
centration of fluorescent compounds. Intensities were
measured as described for a similar system of kidney
proximal tubules (25). Several cellular and luminal
areas were selected, and the average pixel intensity for
each area was calculated. Analysis by high performance
thin layer chromatography of BODIPY Fl-paclitaxel
and NBDL-CS after extraction out of tissue with
ethanol gave no hint for degradation or transforma-
tion of the fluorescent compounds for at least the time
of incubation (≤ 1 hour).
Isolation of endothelial cells and primary culture. Porcine
brain capillary endothelial cells were isolated as
described (26). Primary cultures were prepared accord-
ing to ref. 27. Cells were collected and washed twice in
medium containing 10% horse serum. The final sus-
pension was kept in medium with 20% horse serum
and 10% DMSO and stored in liquid nitrogen until use.
For uptake experiments, cells were seeded onto colla-
gen-coated (Hoffman-LaRoche Ltd., Basel, Switzer-
land) 96-well plates. They were cultured under stan-
dard conditions using isolation medium without
gentamycin, but with 10% horse serum. One day before
transport experiments medium was replaced with 45%
MEM, 45% F12-HAM, 100 µg/ml streptomycin, 100
µg/ml penicillin G, 10 mM HEPES, 2 mM glutamine,
and 550 nM hydrocortisone. For the calcein assay, cells
were washed with KRB buffer (37°C) and incubated
with the test compounds for 5–15 minutes. Calcein-
AM (1 µM) was added, and cells were incubated 15–45
minutes. Then they were washed three times with ice-
cold KRB and lysed with 1% Triton X-100. Fluorescence
was measured using a Fluoroskan Ascent reader (Lab-
Systems GmbH, Frankfurt, Germany).
Western blots. P-gp was detected by Western blot
analysis using the mAb C219 (Alexis Deutschland
GmbH, Grünberg, Germany). The p-gp–overexpress-
ing cell line (MDR+)P388 was used as control. SDS-
PAGE was performed with a Mini-Protean II appara-
tus (Bio-Rad Laboratories GmbH, Munich, Germany).
Proteins were transferred to nitrocellulose membranes
using a Mini Trans-Blot cell for 2.5 hours at 250 mA.
The membranes were incubated with Ab (1:20 dilu-
tion) in PBS containing 0.05% Tween 20, 1% BSA, and
1% milk powder for 2 hours at 37°C. They were
washed four times for 15 minutes and incubated 1
hour at room temperature with horseradish peroxi-
dase–conjugated rabbit anti-mouse IgG (1:1000;
Roche Molecular Biochemicals, Mannheim, Germany)
in PBS containing 1% milk powder and 0.05% Tween
20. After washing, p-gp was detected using enhanced
chemiluminescence (ECL) reagent (Amersham Inter-
national, Buckinghamshire, United Kingdom).
Tumor cell lines and culture conditions. Human U-87 MG
(HTB 14) and U-118 MG (HTB 15) glioblastoma/astro-
cytoma cell lines were obtained from American Type Cul-
ture Collection (Rockville, Maryland, USA). Cell banking
and quality control were performed according to the
“seed stock concept.” U-87 MG cells were grown in
Eagle’s MEM containing L-glutamine, 2.2 g/l NaHCO3,
110 mg/l sodium pyruvate, and 10% FCS. U-118 MG cells
were maintained in DMEM supplemented with 10% FCS.
Cells were cultured in a carbogen atmosphere at 37°C
and were passaged following treatment with trypsin
(0.05%)/EDTA (0.02%). For tumor cell implantation into
nude mice, cells were harvested mechanically, spun down,
and washed twice with serum-free medium.
Chemosensitivity assay. The in vitro antitumor activity
of paclitaxel and the modulating effect of valspodar
were determined by a kinetic assay based on crystal vio-
let staining. Processing procedure and data analysis
were essentially performed as described (28). Paclitaxel
and valspodar were added as 2,000-fold concentrated
feed solutions in 70% ethanol. Doubling-time analysis
of the growth curves of untreated controls was accom-
plished by a polynomial regression fit applying the
least-squares method as earlier reported (29).
1310 The Journal of Clinical Investigation | November 2002 | Volume 110 | Number 9
Immunocytochemistry. Subconfluent tumor cells, cul-
tured on chamber slides, were fixed with 4% phos-
phate buffered paraformaldehyde, pH 7.4, for 30 min-
utes and washed three times with PBS. Endogenous
peroxidase was blocked by incubation in PBS con-
taining 3% H2O2 and 10% methanol for 30 minutes,
followed by two incubations in PBS for 5 minutes.
Nonspecific binding was prevented by 30-minute
incubation in 10% goat serum (Dianova, Hamburg,
Germany), 2.5% skimmed milk powder (Milupa,
Friedrichdorf, Germany), and 0.3% Triton X-100 in
PBS. Subsequently, cells were washed three times with
PBS containing 0.04% Triton X-100 (PBST).
Primary Ab’s AB-1 (PC03) (polyclonal anti-
human/mouse p-gp, mdr; Dianova) and JSB-1/IgG-1
(monoclonal anti-human p-gp; Alexis Deutschland
GmbH) were diluted 1:50 with washing buffer con-
sisting of 10 ml PBST, 100 µl NGS, and 0.3% Triton
X-100. After incubation with primary Ab overnight at
room temperature (RT), the slides were washed three
times with PBS containing 0.34% Triton X-100 and
treated with secondary Ab (for Ab-1, biotinylated
goat anti-rabbit, 1:200; Sigma-Aldrich, Deisenhofen,
Germany; for JSB-1, biotinylated donkey anti-mouse
1:800; Dianova) for 2 hours at RT in a humid cham-
ber. Then, cells were washed three times in PBST and
incubated for 1 hour in horseradish-conjugated
avidin-biotin complex (Vectastain Elite Kit ABC;
Camon Labor Service GmbH, Wiesbaden, Germany)
in PBST. Slides were washed three times for 10 min-
utes in PBST before incubation in a diaminobenzi-
dine (DAB) solution for 10 minutes (0.05% DAB,
0.02% ammonium nickel sulfate in PBST). H2O2 was
added to a final concentration of 0.006%, and slides
were incubated for 10 minutes. Subsequently, they
were washed three times in PBS, processed in an
ascending alcohol series, and mounted in DePex.
Immunohistochemistry. Isolated brain capillaries were
transferred onto slides and fixed for 20 minutes with
3% paraformaldehyde, 0.1% glutardialdehyde, and
3.4% sucrose in PBS. Capillaries were permeabilized
for 15 minutes with 1% (vol/vol) Triton X-100 in PBS.
Then, the capillaries were incubated for 1 hour at
37°C in a humid chamber with primary Ab (150 µl
murine mAbB C219, 1:20 dilution). After washing the
corresponding fluorochrome-conjugated secondary
Ab (150 µl FITC-conjugated rabbit anti-mouse IgG,
1:20 dilution; Hoffmann-LaRoche Ltd.) was added for
1 hour in a humid chamber in the dark.
Murine tissues and intracerebrally growing human
tumors were fixed in Bouin’s solution for 3 days, then
were dehydrated and embedded into paraffin. Sec-
tions of 5-µm thickness were prepared, deparaffinat-
ed with xylene, and rehydrated in a descending alco-
hol series. P-gp was detected with the polyclonal Ab-1
(PC03) Ab (anti-human and murine p-gp; Dianova)
with nuclear fast-red counter staining. The protocol
was the same as for immunocytochemistry except that
the primary Ab was diluted 1:10 with washing buffer.
Pharmacokinetic studies in nude mice. NMRI nu/nu mice
were bred under specified pathogen-free conditions at
26°C, 70% relative humidity, and a 12-hour light/12-
hour dark cycle at the University of Regensburg (30).
They were fed ad libitum with a breeding/maintenance
diet (Altromin GmbH, Lage, Germany) and water con-
taining 1.3 g/l potassium sorbate and 2 g/l chloram-
phenicol; pH was adjusted to 2.5 with HCl. The use of
animals in this study complies with the Guide for the
Care and Use of Laboratory Animals (NIH publication
no. 86-23, revised 1985) and the current German law
on the protection of animals.
Prior to drug administration, 6- to 8-week-old
female NMRI (nu/nu) mice were assigned to groups
of three to four animals per time point. Drinking
solution containing 100 mg/ml valspodar was dilut-
ed to a concentration of 5 mg/ml with its vehicle, a
mixture of Cremophor RH40, ethanol, D,L-α-toco-
pherol, propylene glycol, and Labrafil M2125CS. A
volume of 0.2 ml was administered by gavage per 20
g of body weight, resulting in a dosage of 50 mg val-
spodar per kilogram of body weight. In the same way,
the solvent was applied to the control animals.
For intravenous injection the commercial drug for-
mulation Taxol (6 mg/ml paclitaxel; Bristol-Myers
Squibb) was diluted with 0.9% NaCl to a paclitaxel con-
centration of 1.6 or 0.8 mg/ml. The drug was injected
via the retrobulbar plexus in a volume of 0.1 ml per 20
g of body weight at a dosage of 8 or 4 mg paclitaxel per
kg body weight within approximately 10 seconds. Four
hours before the injection of paclitaxal, either a dose of
50 mg/kg valspodar (valspodar group) or a correspon-
ding volume of the vehicle of valspodar (control) was
administered to the mice by mouth.
To minimize adulterations of the analytical results
by drug in the vasculature, ketamine/xylazine–anes-
thetized mice were killed by cardiac puncture, 1.5, 3,
and 24 hours after intravenous injection, and heparin-
plasma, brain, liver, and kidneys were collected. Tis-
sues were homogenized in 4% BSA within 15 minutes
and shock-frozen in liquid nitrogen. For homogeniza-
tion, each organ was minced into small pieces. One
milliliter 4% BSA solution was added per 150 mg tis-
sue, and homogenization was carried out with a Pot-
ter-Elvehjem homogenizer by 15 strokes. All samples
were stored at –78°C.
Paclitaxel analysis. Tissue extraction was by a modifi-
cation of the method of Sparreboom et al. (31).
Thawed tissue homogenate (1–2 ml) was pipetted into
a glass centrifugation tube with a ground joint. Sam-
ples less than 1 ml were filled up to 1 ml with 4% BSA
solution. Tissue samples underwent diethyl ether
extraction and solid-phase extraction (SPE). Plasma
samples consisted of 250 µl of thawed murine plasma.
Samples with less than 250 µl volume were filled up to
250 µl with human citrate-phosphate-dextrose/plas-
ma. Only plasma samples underwent SPE.
To each sample 10 µl of 50 µM docetaxel solution
was added as internal standard. For docetaxel stock
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solutions Taxotere (80 mg docetaxel per 2 ml of
polysorbate 80; Rhone-Poulenc Rorer, Antony Cedex,
France) was diluted with absolute ethanol. HPLC
analysis was performed on a Thermo Separation Prod-
ucts liquid chromatograph (Thermo Quest; Egelsbach,
Germany). A stainless steel (125 × 4 mm) analytical col-
umn equipped with a guard column (4 × 4 mm), both
packed with 5 µm LiChrospher 100 RP-18 material
(Merck kGaA, SLP PLS, Darmstadt, Germany), was
cooled to 33°C. The mobile phase consisted of ace-
tonitrile/methanol/0.2 M ammonium acetate buffer,
pH 5.0, 38:10.5:51.5 (vol/vol). Ultraviolet detection was
performed at 227 nm, and a washing gradient was
applied after each run (additional 35% vol/vol acetoni-
trile). Injection volumes were either 50 or 100 µl. For
calibration, paclitaxel and docetaxel stock solutions in
anhydrous ethanol, stored at –20°C, were diluted with
mobile phase (1:100) on the day of analysis.
The method of analysis was validated for murine
plasma, brain, liver, and kidney samples (32). Correla-
tion coefficients for paclitaxel calibration curves in the
concentration range 50–1,000 nM were greater than
0.999. Recovery rates for paclitaxel ranged from 50 to
85%, depending on paclitaxel concentration and the
type of tissue. The method’s accuracy for tissue samples
was below 2% for paclitaxel concentrations between
0.667 and 6.67 nmol/g of tissue and better than 8% for
0.133 nmol/g. The precision for these determinations
was better than 10%.
Tumor implantation, treatment, and evaluation. In the
intracerebral model, the parietal bone of anaesthetized
male nude mice (mean body weight 35 g) was drilled
though with a 1-mm-diameter bit 3 mm on the right-
hand side of the sagittal line and 3 mm rostral of the
coronal line. Human U-87 MG cells (106; glioblas-
toma/astrocytoma grade III) or 300,000 U-118 MG
(glioblastoma) tumor cells suspended in 10 µl of
serum-free Eagle’s minimum essential medium were
injected 3 mm deep into the brain tissue, and the
wound was closed with a surgical clamp.
Mice were assigned to three groups (n = 7). The control
group received no medication. Two additional groups
were treated as described for the pharmacokinetic exper-
iment either with a combination of valspodar and pacli-
taxel or the vehicle of valspodar and paclitaxel. Valspo-
dar (50 mg/kg) and vehicle were given to the animals
inoculated with the U-87 MG tumors by mouth 4 hours
before the intravenous injection of two doses of pacli-
taxel, i.e., 4 mg/kg on day 7 and another 2 mg/kg on day
14 after tumor implantation. Animals were killed at day
20, and brains were fixed in Bouin’s solution for histo-
logical examination. Animals bearing intracerebral 
U-118 MG tumors were treated analogously, except
drugs were administered on days 8 and 15, the first pacli-
taxel dose was reduced to 3 mg/kg, and brains were
removed for morphometric analysis on day 35.
Brains were fixed in Bouin’s solution for 3 days,
dehydrated, and embedded into paraffin. Serial 5-µm
coronal sections were prepared every 200 µm (U-87
MG) or 300 µm (U-118 MG) starting and ending 1.5
mm rostral and caudal to the region of tumor cell
implantation, deparaffinated, and stained according
to Masson and Goldner (33). Tumor areas on nine cen-
tral sections were determined per brain morphometri-
cally with the software Metamorph (Visitron Systems
GmbH, Puchheim, Germany), and the tumor volume
in the investigated brain region was calculated.
In the subcutaneous model, approximately 5 × 106
U-118 MG cells (100 µl) were injected into the right flank
of 6-week-old female NMRI (nu/nu) mice. Solid tumors
developed within 8 weeks. For serial passage, the tumors
were cut into 2-mm3 pieces and transplanted subcuta-
neously into the thoracic region with a trocar (30).
Mice were assigned to four groups of ten animals. The
control group received no medication, another group
received the complex vehicle of valspodar, whereas val-
spodar was administered to the third and fourth groups
at a dosage of 10 and 50 mg/kg, respectively. Valspodar
and its vehicle were administered orally twice per week,
resulting in cumulative doses of 120 and 600 mg val-
spodar per kilogram. On day 46 after tumor transplan-
tation the animals were killed by cervical dislocation.
Tumor growth kinetics was recorded by measuring
tumor diameters with an electronic caliper. Tumor
areas were calculated as the product of two perpendi-
cular diameters, of which one represents the largest
possible diameter of the tumor. Tumor size and the
weight of the animals were measured twice a week.
Statistical analysis. Data are presented as mean values
plus or minus SEM and were evaluated by one-way
ANOVA using SPSS 10.0 for Windows. Except for the
pharmacokinetic results, which were analysed non-
parametrically by the U test according to Mann and
Whitney, the unpaired Student t test for inhomoge-
neous variances was applied. P values less than or equal
to 0.05 were considered statistically significant.
Results
Isolated brain capillaries. Integrity of isolated capillar-
ies was checked by microscopy. After a 60- to 80-
minute incubation with FITC-dextran 4000 as a
marker for paracellular permeation, no fluorescence
was detected inside the capillary lumina by confocal
scanning microscopy, indicating that tight junction
integrity was maintained and that the endothelium
of isolated capillaries is a significant barrier to diffu-
sion of large molecules, which is consistent with in
vivo observations.
Immunohistochemical assessment of p-gp in intact
rat capillaries (Figure 1a) showed the primary local-
ization of the export protein in the luminal mem-
brane, with only weak staining at the outer membrane.
Presence of p-gp was confirmed by Western blots of
porcine brain capillary endothelial cells that were cul-
tured for 7 days prior to transport studies (Figure 1b).
In the human brain, p-gp (MDR1) was found in capil-
laries in the cortex, the hippocampus, the cerebellum,
and the spinal cord, but not in submeningeal blood
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vessels and the vessels of the choroid plexus (34). In
coronal sections of the brains of NMRI nude mice, p-
pg (AB-1 Ab’s) was not only detected in capillaries of
the cortex but also in deeper medullar regions. Figure
1c shows that not only small capillaries and larger
blood vessels in the cortex stained positive, but also
that p-gp is expressed in submeningeal arteries and
veins. The immunopositive small capillaries were
unevenly distributed in the cerebral parenchyma,
reflected in a somewhat lower density between the
outer band of Baillarger and Kaes-Bechterew’s band
(results not shown). Hepatic bile canaliculi, renal prox-
imal tubules, and small intestinal brush borders also
stained positive (not shown).
Figure 2a shows the time course of BODIPY Fl-pacli-
taxel accumulation in intact rat brain capillaries. Fluo-
rescence in cells and capillary lumina rapidly increased,
reaching steady-state values after 30–45 minutes. At
steady state, luminal fluorescence was about three
times cellular fluorescence. Medium fluorescence was
barely detectable, so BODIPY Fl-paclitaxel clearly accu-
mulated in the cells and lumina. In capillaries exposed
to 1 mM NaCN, steady-state luminal fluorescence was
significantly reduced compared with controls, but cel-
lular fluorescence was unchanged (Figure 2a). With
NaCN, luminal fluorescence approached cellular lev-
els. Thus, accumulation of BODIPY Fl-paclitaxel with-
in the cells was not energy dependent, probably reflect-
ing passive diffusion, binding to cellular elements, and
partitioning into membranes. In contrast, movement
of BODIPY Fl-paclitaxel from cell to lumen was energy
dependent, suggesting uphill transport. Luminal accu-
mulation of BODIPY Fl-paclitaxel was reduced in a
concentration-dependent manner by unlabeled pacli-
taxel, suggesting that both compounds interact with
the same transporter. Luminal accumulation of BOD-
IPY Fl-paclitaxel was also reduced by the p-gp inhibitor,
valspodar (Figure 2b). Neither paclitaxel nor valspodar
reduced cellular fluorescence. In contrast, the Mrp
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Figure 1
(a) Immunostaining of p-gp in a freshly isolated rat brain capillary
(primary Ab: MAB C219; secondary Ab: FITC-conjugated rabbit anti-
mouse IgG). (b) P-gp detection by Western blot using the MAB
C219. Left lane: brain capillaries; right lane: p-gp overexpressing cell
line (MDR+)P388 as positive control. (c) Immunostaining of coro-
nar sections of the brains of nude mice, using the polyclonal AB-1
Ab. Healthy animal, with P-gp expression in capillaries and larger
blood vessels in the cerebrum (bottom) and the submeningeal arter-
ies and veins (top). (d) Intracerebral human glioblastoma (U-87
MG) with immunopositive capillary endothelia and negative tumor
cells. The arrow points to the ependyma.
Figure 2
(a) Time-dependent accumulation of BODIPY Fl-paclitaxel in cells and lumens of isolated rat brain capillaries in the absence and presence
of 1 mM NaCN. Means ± SEM, n = 10–12, P = 0.05. (b) Accumulation of BODIPY Fl-paclitaxel and NBDL-CS (c), respectively, in the lumens
of isolated capillaries in the absence and presence of unlabeled paclitaxel, the p-gp blocker valspodar, and the mrp2 substrate LTC4. The flu-
orescent compounds were added at concentrations of 1 µM. Means ± SEM, n = 10–12. *Significantly different from controls; P = 0.05.
inhibitor leukotriene C4 (LTC4), was without effect. We
also examined the effects of paclitaxel on the transport
of NBDL-CS, a fluorescent p-gp substrate (25, 35). As
with BODIPY Fl-paclitaxel, luminal accumulation of
NBDL-CS was inhibited by valspodar and by paclitax-
el (Figure 2c). Cellular fluorescence was not affected by
valspodar or paclitaxel (not shown).
Calcein-AM assay in primary cultures of porcine brain cap-
illary endothelial cells. We confirmed the above results
using a fluorescence-based p-gp assay and monolayer
cultures of porcine brain capillary endothelial cells
expressing p-gp. In this assay calcein-AM is excluded
from the cells by p-gp. When p-gp is inhibited, e.g., by
competitors, the compound accumulates intracellu-
larly and is hydrolyzed to calcein. This fluorescent
organic anion is trapped within the cells, and the
accumulation is taken as a measure of transporter
inhibition. Under control conditions, calcein accu-
mulation was very low. However, when valspodar or
paclitaxel was added, concentration-dependent
increases in calcein accumulation were observed.
Although paclitaxel was not quite as potent an
inhibitor of p-gp as valspodar, it was also effective in
the µM concentration range (Figure 3).
Pharmacokinetic studies in nude mice. In mice given 8
mg/kg paclitaxel intravenously, concentrations in plas-
ma averaged 1.45 ± 0.28 µM and 0.48 ± 0.04 µM 1.5 and
3 hours after dosing, respectively. Pretreatment with
valspodar (50 mg/kg by mouth) slightly increased plas-
ma concentration at 1.5 hours (2.51 ± 0.64 µM) and sig-
nificantly increased plasma concentration after 3 hours
(3.22 ± 0.20 µM). For both groups, plasma paclitaxel
concentrations were below the limit of detection 24
hours after injection.
In mice that received paclitaxel alone, brain levels
of the drug were always near the limit of detection.
Coadministration of valspodar increased the pacli-
taxel levels in the brain by about one order of magni-
tude. In contrast to plasma, liver, and kidney (Table
1) this elevation in brain paclitaxel was rapid and
long lasting; i.e., the levels were elevated after 1.5
hours and remained high for at least 24 hours after
dosing (see Figure 5).
In clinical trials, paclitaxel doses had to be reduced
by 30–60% if valspodar was coadministered (36, 37).
Therefore, paclitaxel tissue concentrations were deter-
mined in mice that were pretreated with valspodar
but received half the paclitaxel dose (4 mg/kg; Figure
4). Despite the reduced dose, 24 hours after injection
paclitaxel levels were three times higher in the brains
of these pretreated mice than in animals that had
received 8 mg paclitaxel/kg without valspodar (Figure
5). Paclitaxel levels in liver and kidney of the animals
in the PSC 833 group with the reduced paclitaxel dose
were roughly comparable to the PSC 833 group with
the full paclitaxel dose.
Characterization of the human glioblastoma cell lines.
When diagnosed, some neuroepithelial tumors, espe-
cially astrocytoma and neuroblastoma, exhibit the
classical primary MDR phenotype (38–40). Moreover,
in astrocytoma, p-gp expression seems to be positively
correlated with tumor grade (41). Therefore, the
human U-87 MG and the U-118 MG glioblastoma/
astrocytoma cells were checked for p-gp expression
using the monoclonal JSB-1 Ab, which recognizes an
uncharacterized epitope on the cytoplasmic side of the
human MDR1 p-gp (42), and using the polyclonal Ab
AB-1, which binds to a cytoplasmic domain at the C
terminus of human MDR1 p-gp and murine mdr1a
and mdr1b with similar affinity. P-gp–overexpressing
KB-V1 cells, cultured in the presence of 300 ng/ml 
vinblastine, were used as positive controls. Whereas 
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Figure 3
Increase of intracellular fluorescence intensity (free calcein) in mono-
layers of porcine brain capillary endothelial cells. Presence of the p-gp
substrates valspodar (filled circles) and paclitaxel (filled triangles) results
in an increased fluorescence intensity, whereas penicillin (open circles)
has no effect (means ± SEM, n = 6).
Table 1
Effect of valspodar coadministration on paclitaxel levels (mean values ± SEM) in liver and kidney of nude mice (n = 3) after intravenous injec-
tion of 8 mg/kg paclitaxel
Mean paclitaxel level ± SEM (nmol/g)
Liver Kidney
Time (h) Paclitaxel Valspodar plus paclitaxel Paclitaxel Valspodar plus paclitaxel
1.5 33.49 ± 1.87 18.50 ± 1.18A 12.25 ± 0.63 15.66 ± 0.46A
3 18.03 ± 2.98 20.17 ± 0.74 7.87 ± 0.65 17.87 ± 0.66A
24 0.91 ± 0.24 2.28 ± 0.34A 0.37 ± 0.24 2.62 ± 0.69A
Four hours before intravenous application the animals were treated with the vehicle of valspodar by mouth (paclitaxel) or 50 mg/kg valspodar by mouth (val-
spodar plus paclitaxel). AStatistically significant differences (P ≤ 0.05).
KB-V1 cells stained intensely with both Ab’s, U-87 MG
and U-118 MG glioma cells did not.
When inoculated intracerebrally, the human
glioblastoma cell lines U-87 MG and U-118 MG
formed solid tumors as shown in the Figure 1d.
Immunostaining with the AB-1 Ab revealed p-gp
expression in the neovasculature, which is consistent
with the clinical situation (43–45). On the contrary, in
agreement with the results of immunocytochemistry
the tumor cells did not exhibit the MDR1 phenotype
and did not stain with the monoclonal anti-human 
p-gp 170 JSB-1 Ab (not shown).
Within the tumor, blood vessels of varying diameters
were immunopositive. Staining intensity of the tumor
endothelia depended on tumor size and localization.
Highest p-pg expression was observed in small neo-
plasms, especially in the proliferating peripheral region.
In this area, density and staining intensity of the newly
formed capillaries were higher than of the blood vessels
in the surrounding brain parenchyma. In contrast,
when the glioma was implanted into nude mice subcu-
taneously, the tumor vessels failed to express p-gp (46).
To determine the sensitivity of U-87 MG and U-118
MG glioblastoma cells against paclitaxel and valspodar,
the cells were exposed to the drugs during the whole
incubation period of up to 300 hours. Doubling times
substantially differed between the two cell lines. For 
U-87 MG a mean minimal doubling time (tD) of 27.5
hours was determined, whereas proliferation of U-118
MG cells with a tD of 50 hours was significantly slower
(47). At a concentration of 100 nM (a typical peak
plasma concentration), paclitaxel was cytostatic on 
U-87 MG cells, whereas proliferation of the U-118 MG
cells had already ceased at 5 nM. At a concentration of
1 µM, valspodar did not affect proliferation of either
cell line. Combining 1 µM valspodar with weakly cyto-
toxic concentrations of doxorubicin, etoposide, and
paclitaxel, known substrates of p-gp 170, failed to
enhance the cytotoxicity of these p-gp substrates.
Therefore, both cell lines appear to be well suited to
investigate the effect of valspodar paclitaxel coapplica-
tion at the blood-brain barrier.
Paclitaxel effects on intracerebral growth of human
glioma. Two experiments were carried out to deter-
mine whether the rise in the brain levels of paclitaxel
in animals pretreated with valspodar could provide a
therapeutic benefit. In the first experiment, human
U-87 MG glioblastoma cells were implanted intrac-
erebrally into nude mice. This procedure results in
aggressively growing intracerebral neoplasms (48). As
described above, this cell line is relatively insensitive
to paclitaxel and certain other chemotherapeutic
agents in vitro. The animals (n = 7–8) were dosed with
4 mg/kg paclitaxel on day 7 after implantation and
with 2 mg/kg paclitaxel on day 14, without and with
50 mg/kg valspodar 4 hours before each paclitaxel
dose. Brains were collected on day 20, and the intrac-
erebral tumor tissue was quantified by morphome-
try. In this experiment, there were no statistically sig-
nificant differences in the mean tumor volumes
within the three groups: 7.4 ± 1.3 mm3 in the control,
8.6 ± 1.2 mm3 in the paclitaxel, and 7.8 ± 1.3 mm3 in
the paclitaxel-valspodar group. Whereas the mean
body weight of the control animals increased by 5%,
there was a significant reduction of mean body
weight in both treatment groups with a decrease by
9% in the paclitaxel group and a weight loss by 17%
in the paclitaxel-valspodar group during the course
of the experiment.
In the second study with intracerebral U-118 MG
tumors, paclitaxel dosage was reduced to avoid weight
loss. A control group received no medication; a second
group received paclitaxel 8 days (3 mg/kg) and 15 days
(2 mg/kg) after tumor implantation; a third group
received the same regimen of paclitaxel dosing, but in
combination with 50 mg/kg valspodar 4 hours before
each paclitaxel dose. Mice were killed 35 days after
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Figure 4
Application scheme of PSC 833 and paclitaxel to nude mice. Each
group consisted of three to four nude mice per observation time after
intravenous injection.
Figure 5
Effect of valspodar coadministration on the paclitaxel brain levels
in nude mice after intravenous injection of 8 mg/kg paclitaxel. Four
hours before intravenous application the animals were treated with
the vehicle of valspodar by mouth (control, open squares) or 50
mg/kg valspodar by mouth (valspodar group, filled squares). Brain
levels for a valspodar group with reduced paclitaxel dose (4 mg/kg,
open circles) were investigated 24 hours after intravenous injection.
Means ± SEM, n = 3–4. Compared with the respective controls, all
values in the valspodar groups were significantly (P ≤ 0.05) higher.
implantation, and the tumor volume in each brain was
determined morphometrically (n = 5). Treatment with
paclitaxel alone did not reduce the tumor volume sig-
nificantly, whereas valspodar plus paclitaxel decreased
the tumor volume by 90% (P < 0.05; Figure 6). As shown
in Figure 6 (inset), the regimen was not compromised
by intolerable toxicity. This result demonstrates that
coadministration of valspodar can improve the thera-
peutic benefit of paclitaxel for brain tumor treatment.
Clearly, in vivo the solid U-118 MG tumors were more
sensitive to paclitaxel than the solid U-87 MG tumors,
a result that agrees with proliferation kinetics and drug
sensitivity of these cell lines in vitro (46, 47).
Effect of valspodar on subcutaneous growth of implanted
human glioma. Recently, valspodar was reexamined as an
antitumor agent in vitro (49). We considered the possi-
ble contribution of valspodar to glioma cytotoxicity in
an experiment with nude mice bearing U-118 MG
glioblastoma subcutaneously. In a 46-day experiment,
mice with implanted tumors were given intravenously
120 or 600 mg/kg valspodar, vehicle alone, or no treat-
ment. At the end of the experiment, there were no sta-
tistically significant effects on tumor growth among
the untreated control group, the vehicle group, and the
two valspodar groups (Table 2), nor was there a hint of
systemic or CNS toxicity.
Discussion
Malignant brain tumors (higher-grade gliomas) are rarely
cured by surgery and/or radiotherapy, and chemothera-
py has been of limited value, especially as long as the
blood-brain barrier remains intact. In addition, the brain
is sanctuary for metastases in cancer patients otherwise
responding to cytostatic drugs such as paclitaxel (50).
One aim of this study was to find a mechanistic
explanation for the low permeability of paclitaxel
using in vitro and in vivo studies. Since paclitaxel is
excluded from many tumor cells by p-gp, it is likely
that this drug efflux pump also limits the access of the
drug to the brain. Brain capillaries express p-gp and
other ATP binding cassette (ABC) transporters at their
luminal membrane (16, 51). To study the impact of
ABC transporters on paclitaxel transport we applied a
newly developed approach using isolated rat brain cap-
illaries, fluorescent substrates, and confocal imaging.
Isolated rat brain capillaries accumulated fluorescent-
ly labeled paclitaxel within the lumina. This accumu-
lation was up to 3.5-fold above the cellular accumula-
tion and showed all the hallmarks of specific active
transport. It was blocked when metabolism was inhib-
ited by NaCN and when unlabeled drug or the p-gp
modifier, valspodar, were added. Unlabeled paclitaxel
inhibited the secretion of NBDL-cyclosporin, a p-gp
substrate. In cultured endothelial cells from porcine
brain, paclitaxel enhanced in a dose-dependent man-
ner the intracellular accumulation of calcein derived
from calcein-AM, a p-gp substrate that is otherwise
excluded from the cells. All results point to p-gp as a
major obstacle to paclitaxel entry into the CNS.
Valspodar is a potent inhibitor of p-gp that alters
drug transport across barrier and excretory tissues in
vitro and in vivo. As a result, it has the potential to alter
the pharmacokinetics of the many therapeutic agents
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Figure 6
Effect of valspodar/paclitaxel coadministration on the intracerebral
growth of the human U 118 MG glioblastoma in nude mice. Con-
trols received no medication, the paclitaxel group received the vehi-
cle of valspodar 4 hours before injection of paclitaxel, and the pacli-
taxel-valspodar group received 50 mg/kg valspodar by mouth before
injection of paclitaxel. Animals were treated in this way on day 8 (3
mg/kg paclitaxel) and day 15 (2 mg/kg paclitaxel) after implantation
of tumors. Thirty-five days after tumor implantation the brains of the
animals were collected and the tumor volumes determined morpho-
metrically. The figure shows mean values ± SEM (n = 5). Inset:
Change of mean body weight as an indicator of toxicity. Control,
open squares; paclitaxel, open circles; paclitaxel-valspodar, filled
squares. The arrows indicate drug administration.
Table 2
Effect of valspodar on the growth of subcutaneously implanted U-118 MG glioma 
Mean tumor area ± SEM (mm2)
Treatment group (n = 10) Day
0 11 25 36 46
Control 3.5 ± 0.47 6.64 ± 0.82 20.2 ± 4.06 24.5 ± 5.62 36.5 ± 10.05
10 mg/kg valspodar 2.9 ± 0.48 9.1 ± 1.22 18.0 ± 3.60 41.0 ± 9.96 53.7 ± 27.80
P (0.423) (0.104) (0.699) (0.141) (0.550)
50 mg/kg valspodar 3.4 ± 0.43 7.2 ± 0.88 18.3 ± 2.53 28.3 ± 4.48 35.2 ± 12.94
P (0.933) (0.645) (0.719) (0.608) (0.948)
Valspodar was administered orally twice per week resulting in cumulative doses of 120 and 600 mg valspodar per kilogram. Treatment was started on day 1.
ASignificance level with respect to the control.
that are p-gp substrates, leading to longer terminal half
lives and lower excretion rates. Such effects have been
observed for paclitaxel and other P-gp substrates in
clinical and preclinical investigations (23, 36, 37).
Other groups have shown that transporter abla-
tion/inhibition increases drug delivery to the CNS. For
example, van Asperen et al. (52) observed the tissue dis-
tribution of vinblastine in mice with homozygously dis-
rupted mdr1a genes (mdr1a encodes for P-gp in mice
predominantly expressed at the blood-brain barrier)
and in the wild-type species. As in our work, they found
the highest increase in tissue levels of mdr1a-deficient
mice compared with the wild-type species for the brain,
where 7–46 times higher vinblastine levels were found,
depending on time and dose. Also consistent with our
results, vinblastine levels in liver and kidney were sig-
nificantly higher in knockout mice compared with wild-
type animals no earlier than 24 hours after drug admin-
istration. The area under the plasma-time curve was
found to be 1.4–1.6 times higher in mdr1a-deficient
mice. Our results agree in principle with an increased
plasma area under the curve. However, this fact cannot
explain the six- to eightfold higher paclitaxel concen-
trations in the brain of valspodar pretreated animals
within the first observation period of 1.5 hours, since
the plasma levels were only slightly elevated compared
with paclitaxel application alone. This supports the
interpretation that the inhibition of p-gp by valspodar
reduces paclitaxel efflux from the brain. With the avail-
able analytical techniques it is impossible to determine
whether the drug is homogeneously distributed or accu-
mulated by endothelial or other cells.
Drion et al. (53) perfused brains of rats for 20 seconds
with radiolabeled vinblastine and analyzed brain sec-
tions. For rats that received 10 mg/kg valspodar intra-
venously 5 minutes before infusion, nine times higher
vinblastine levels were found in all sections of gray
brain tissue compared with rats that received no val-
spodar. These experiments are especially interesting,
because the administration of valspodar has no influ-
ence on drug concentration in the perfusate and the
influence of valspodar on the pharmacokinetics of the
cytostatic is of no relevance.
The present results also show that valspodar pre-
treatment not only increased brain levels of paclitaxel,
but that it also produced a therapeutic effect on a pacli-
taxel-sensitive transplanted tumor. Although paclitax-
el therapy by itself did not affect the volume of intrac-
erebrally implanted U-118 MG tumors, combined
valspodar-paclitaxel therapy resulted in a significant
decrease in tumor volume (Figure 6). In contrast, nei-
ther paclitaxel nor valspodar-paclitaxel therapy affect-
ed the volume of implanted U-87 MG tumors derived
from a cell line that is not paclitaxel sensitive. Neither
glioblastoma cell line exhibited a multidrug-resistance
phenotype. Thus, the statistically significant reduction
in tumor volume caused by valspodar coadministra-
tion was due to increased paclitaxel levels in the brain,
a result of inhibition of P-gp–mediated transport at the
blood-brain barrier. Circumvention of multidrug
resistance at the tumor cell was not a factor. These
findings suggest that coadministration of valspodar
can be of clinical benefit for the chemotherapeutical
treatment of brain tumors sensitive to cytostatics,
which are substrates of P-gp. The chemotherapy of
other cancers expressing the MDR phenotype (e.g.,
colon carcinoma and kidney cancer) could also benefit
from the coadministration of P-gp inhibitors such as
valspodar. In the clinics, the risk of increased (CNS)
toxicity, which cannot be totally excluded by our pre-
clinical studies, might require an adjusted paclitaxel
dose when used in combination with valspodar or
other p-gp inhibitors such as elacridar.
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